Cross-Platform in-silico Analyses Exploring Tumor Immune Microenvironment with Prognostic Value in Triple-Negative Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Glodzik D, Bosch A, Hartman J, et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun. 2020;11(1):3747. doi:10.1038/s41467-020-17537-2
   PubMed Web of Science ®Google Scholar
• Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020;6:54. doi:10.1038/s41523-020-00197-2
   PubMed Web of Science ®Google Scholar
• Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–1698. doi:10.1158/1078-0432.Ccr-14-0432
   PubMed Web of Science ®Google Scholar
• Kok VC. Hepatic metastasectomy and paclitaxel provide long-term survival for a young woman with recurrent triple-negative metastatic breast cancer: 16 years follow-up. J Cancer Res Ther. 2018;14(3):722–723. doi:10.4103/0973-1482.179087
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi:10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 2020;21(1):44–59. doi:10.1016/s1470-2045(19)30689-8
   PubMed Web of Science ®Google Scholar
• Oshi M, Asaoka M, Tokumaru Y, et al. Abundance of regulatory T cell (Treg) as a predictive biomarker for neoadjuvant chemotherapy in triple-negative breast cancer. Cancers (Basel). 2020;12(10). doi:10.3390/cancers12103038
   Web of Science ®Google Scholar
• Bianchini G, Qi Y, Alvarez RH, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010;28(28):4316–4323. doi:10.1200/jco.2009.27.2419
   PubMed Web of Science ®Google Scholar
• Kok VC. Current understanding of the mechanisms underlying immune evasion from PD-1/PD-L1 immune checkpoint blockade in head and neck cancer. Front Oncol. 2020;10:268. doi:10.3389/fonc.2020.00268
   PubMed Web of Science ®Google Scholar
• Bouzidi L, Triki H, Charfi S, et al. Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues. Clin Breast Cancer. 2021;21(6):e738–e747. doi:10.1016/j.clbc.2021.02.003
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi:10.1038/nri.2017.49
   PubMed Web of Science ®Google Scholar
• Sivadas A, Kok VC, Ng KL. Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers. Breast Cancer Res Treat. 2022. doi:10.1007/s10549-022-06567-7
   PubMed Web of Science ®Google Scholar
• Mapiye DS, Christoffels AG, Gamieldien J. Identification of phenotype-relevant differentially expressed genes in breast cancer demonstrates enhanced quantile discretization protocol’s utility in multi-platform microarray data integration. J Bioinform Comput Biol. 2016;14(5):1650022. doi:10.1142/s0219720016500220
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Colaprico A, Silva TC, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12(1):6276. doi:10.1038/s41467-021-26502-6
   PubMed Web of Science ®Google Scholar
• De Mattos-arruda L, Sammut SJ, Ross EM, et al. The genomic and immune landscapes of lethal metastatic breast cancer. Cell Rep. 2019;27(9):2690–2708.e10. doi:10.1016/j.celrep.2019.04.098
   PubMed Web of Science ®Google Scholar
• Wang CCN, Li CY, Cai JH, et al. Identification of prognostic candidate genes in breast cancer by integrated bioinformatic analysis. J Clin Med. 2019;8(8). doi:10.3390/jcm8081160
   Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. doi:10.1038/s41587-019-0114-2
   PubMed Web of Science ®Google Scholar
• Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol Biol. 2020;2120:223–232. doi:10.1007/978-1-0716-0327-7_16
   PubMedGoogle Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Galili T, O’Callaghan A, Sidi J, Sievert C. heatmaply: an R package for creating interactive cluster heatmaps for online publishing. Bioinformatics. 2018;34(9):1600–1602. doi:10.1093/bioinformatics/btx657
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Chen EY, Xu H, Gordonov S, Lim MP, Perkins MH, Ma’ayan A. Expression2Kinases: mRNA profiling linked to multiple upstream regulatory layers. Bioinformatics. 2012;28(1):105–111. doi:10.1093/bioinformatics/btr625
   PubMed Web of Science ®Google Scholar
• Clarke DJB, Kuleshov MV, Schilder BM, et al. eXpression2Kinases (X2K) Web: linking expression signatures to upstream cell signaling networks. Nucleic Acids Res. 2018;46(W1):W171–w179. doi:10.1093/nar/gky458
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.Cd-12-0095
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Berger H, Vegran F, Chikh M, et al. SOCS3 transactivation by PPARgamma prevents IL-17-driven cancer growth. Cancer Res. 2013;73(12):3578–3590. doi:10.1158/0008-5472.CAN-12-4018
   PubMed Web of Science ®Google Scholar
• Ahmed M, Gaffen SL. IL-17 inhibits adipogenesis in part via C/EBPalpha, PPARgamma and Kruppel-like factors. Cytokine. 2013;61(3):898–905. doi:10.1016/j.cyto.2012.12.007
   PubMed Web of Science ®Google Scholar
• Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3):263–270. doi:10.1038/85820
   PubMed Web of Science ®Google Scholar
• Wei ZY, Li HS, Zhou JY, et al. [Mechanism of transcriptional regulation of Meox1 by transforming growth factor beta (1) and its effect on cell migration of adult human dermal fibroblasts]. Zhonghua Shao Shang Za Zhi. 2020;36(3):224–233, Chinese. doi:10.3760/cma.j.cn501120-20200109-00014
   PubMedGoogle Scholar
• Yu C, Niu X, Du Y, et al. IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment. Cancer Immunol Immunother. 2020;69(1):115–126. doi:10.1007/s00262-019-02445-2
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu E, Zhang J, Chen M, Flores E, Chen X. The Rbm38-p63 feedback loop is critical for tumor suppression and longevity. Oncogene. 2018;37(21):2863–2872. doi:10.1038/s41388-018-0176-5
   PubMed Web of Science ®Google Scholar
• Burns LA, Maroof A, Marshall D, et al. Presence, function, and regulation of IL-17F-expressing human CD4(+) T cells. Eur J Immunol. 2020;50(4):568–580. doi:10.1002/eji.201948138
   PubMed Web of Science ®Google Scholar
• Hod-Dvorai R, Jacob E, Boyko Y, Avni O. The binding activity of Mel-18 at the Il17a promoter is regulated by the integrated signals of the TCR and polarizing cytokines. Eur J Immunol. 2011;41(8):2424–2435. doi:10.1002/eji.201141620
   PubMed Web of Science ®Google Scholar
• Aboulnasr F, Hazari S, Nayak S, et al. IFN-lambda inhibits MiR-122 transcription through a Stat3-HNF4alpha inflammatory feedback loop in an IFN-alpha resistant HCV cell culture system. PLoS One. 2015;10(12):e0141655. doi:10.1371/journal.pone.0141655
   PubMed Web of Science ®Google Scholar
• Kim YD, Kim YH, Cho YM, et al. Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models. Diabetologia. 2012;55(5):1482–1494. doi:10.1007/s00125-012-2494-4
   PubMed Web of Science ®Google Scholar
• Li G, Kong B, Zhu Y, et al. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol Appl Pharmacol. 2013;272(2):299–305. doi:10.1016/j.taap.2013.06.016
   PubMed Web of Science ®Google Scholar
• Shen J, Sun X, Pan B, et al. IL-17 induces macrophages to M2-like phenotype via NF-κB. Cancer Manag Res. 2018;10:4217–4228. doi:10.2147/cmar.S174899
   PubMed Web of Science ®Google Scholar
• Saha S, Zhang Y, Wilson B, Abounader R, Dutta A. The tumor-suppressive long noncoding RNA DRAIC inhibits protein translation and induces autophagy by activating AMPK. J Cell Sci. 2021;134(24). doi:10.1242/jcs.259306
   PubMed Web of Science ®Google Scholar
• Alt EU, Wörner PM, Pfnür A, et al. Targeting TRAF3IP2, compared to Rab27, is more effective in suppressing the development and metastasis of breast cancer. Sci Rep. 2020;10(1):8834. doi:10.1038/s41598-020-64781-z
   PubMed Web of Science ®Google Scholar
• Herjan T, Hong L, Bubenik J, et al. IL-17-receptor-associated adaptor Act1 directly stabilizes mRNAs to mediate IL-17 inflammatory signaling. Nat Immunol. 2018;19(4):354–365. doi:10.1038/s41590-018-0071-9
   PubMed Web of Science ®Google Scholar
• Bareche Y, Buisseret L, Gruosso T, et al. Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach. J Natl Cancer Inst. 2020;112(7):708–719. doi:10.1093/jnci/djz208
   PubMedGoogle Scholar
• Chung AS, Wu X, Zhuang G, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19(9):1114–1123. doi:10.1038/nm.3291
   PubMed Web of Science ®Google Scholar
• Deng J, Thennavan A, Shah S, et al. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. Breast Cancer Res Treat. 2020;185:85–94. doi:10.1007/s10549-020-05936-4
   PubMed Web of Science ®Google Scholar
• Deng L, Lu D, Bai Y, Wang Y, Bu H, Zheng H. Immune profiles of tumor microenvironment and clinical prognosis among women with triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(12):1977–1985. doi:10.1158/1055-9965.Epi-19-0469
   PubMed Web of Science ®Google Scholar
• Vangangelt KMH, van Pelt GW, Engels CC, et al. Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Breast Cancer Res Treat. 2018;168(3):601–612. doi:10.1007/s10549-017-4617-6
   PubMed Web of Science ®Google Scholar
• Zheng S, Zou Y, Xie X, et al. Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer. Int J Cancer. 2020;147(2):542–553. doi:10.1002/ijc.33009
   PubMed Web of Science ®Google Scholar
• Karn T, Jiang T, Hatzis C, et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol. 2017;3(12):1707–1711. doi:10.1001/jamaoncol.2017.2140
   PubMed Web of Science ®Google Scholar
• Deng J, Thennavan A, Shah S, et al. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. Breast Cancer Res Treat. 2021;185(1):85–94. doi:10.1007/s10549-020-05936-4
   PubMed Web of Science ®Google Scholar
• Lambert SA, Jolma A, Campitelli LF, et al. The human transcription factors. Cell. 2018;172(4):650–665. doi:10.1016/j.cell.2018.01.029
   PubMed Web of Science ®Google Scholar
• Tsai YF, Huang CC, Lin YS, et al. Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis. Cancer Immunol Immunother. 2021;70(8):2339–2351. doi:10.1007/s00262-021-02867-x
   PubMed Web of Science ®Google Scholar
• Shuai C, Yang X, Pan H, Han W. Estrogen receptor downregulates expression of PD-1/PD-L1 and infiltration of CD8(+) T cells by inhibiting IL-17 signaling transduction in breast cancer. Front Oncol. 2020;10:582863. doi:10.3389/fonc.2020.582863
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206(7):1457–1464. doi:10.1084/jem.20090207
   PubMed Web of Science ®Google Scholar
• Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010;184(3):1630–1641. doi:10.4049/jimmunol.0902813
   PubMed Web of Science ®Google Scholar
• Ruhland MK, Loza AJ, Capietto AH, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun. 2016;7:11762. doi:10.1038/ncomms11762
   PubMed Web of Science ®Google Scholar
• Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6:10. doi:10.1186/s40364-018-0122-2
   PubMed Web of Science ®Google Scholar
• Liu YH, Tsai YS, Lin SC, et al. Quantitative PPARγ expression affects the balance between tolerance and immunity. Sci Rep. 2016;6:26646. doi:10.1038/srep26646
   PubMed Web of Science ®Google Scholar
• Faucheux L, Grandclaudon M, Perrot-Dockès M, et al. A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. Oncoimmunology. 2019;8(9):e1624130. doi:10.1080/2162402x.2019.1624130
   PubMed Web of Science ®Google Scholar
• Chen J, Ye X, Pitmon E, et al. IL-17 inhibits CXCL9/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors. J Immunother Cancer. 2019;7(1):324. doi:10.1186/s40425-019-0757-z
   PubMed Web of Science ®Google Scholar
• Dadaglio G, Fayolle C, Oberkampf M, et al. IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8(+) T-cell responses. Oncoimmunology. 2020;9(1):1758606. doi:10.1080/2162402x.2020.1758606
   PubMed Web of Science ®Google Scholar
• Kaewkangsadan V, Verma C, Eremin JM, Cowley G, Ilyas M, Eremin O. Crucial contributions by T lymphocytes (effector, regulatory, and checkpoint inhibitor) and cytokines (TH1, TH2, and TH17) to a pathological complete response induced by neoadjuvant chemotherapy in women with breast cancer. J Immunol Res. 2016;2016:4757405. doi:10.1155/2016/4757405
   PubMed Web of Science ®Google Scholar
• Li Q, Ngo PT, Egilmez NK. Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy. Cancer Immunol Immunother. 2021;70(6):1789–1796. doi:10.1007/s00262-020-02795-2
   PubMed Web of Science ®Google Scholar
• Moaaz M, Lotfy H, Motawea MA, Fadali G. The interplay of interleukin-17A and breast cancer tumor microenvironment as a novel immunotherapeutic approach to increase tumor immunogenicity. Immunobiology. 2021;226(2):152068. doi:10.1016/j.imbio.2021.152068
   PubMed Web of Science ®Google Scholar
• Peng DH, Rodriguez BL, Diao L, et al. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat Commun. 2021;12(1):2606. doi:10.1038/s41467-021-22875-w
   PubMed Web of Science ®Google Scholar
• Thibaudin M, Chaix M, Boidot R, et al. Human ectonucleotidase-expressing CD25(high) Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. Oncoimmunology. 2016;5(1):e1055444. doi:10.1080/2162402x.2015.1055444
   PubMed Web of Science ®Google Scholar
• Wang X, Sun R, Hao X, Lian ZX, Wei H, Tian Z. IL-17 constrains natural killer cell activity by restraining IL-15-driven cell maturation via SOCS3. Proc Natl Acad Sci U S A. 2019;116(35):17409–17418. doi:10.1073/pnas.1904125116
   PubMed Web of Science ®Google Scholar